STM JOURNALS

International Journal of
Brain Sciences

Volume 1, Issue 2, 2024
July-December
DOI (Journal): 10.37591/IJBS

https://journals.stmjournals.com/ijbs

Review IJBS

An Extensive Analysis of Computer-aided Drug Design for Novel Psychotropic and Neurological Substances

Mohd. Wasiullah[1], Piyush Yadav[2], Safiya Sajid[3], Satish Kumar Yadav[4,*], Anjali Maurya[5]

Abstract

A comprehensive review of the use of computer-aided drug design (CADD) in the creation of innovative neurologic and neuropsychiatric medications is given in this article. It discusses the challenges in traditional drug discovery approaches and highlights the role of computational methods in accelerating the identification and optimization of drug candidates targeting psychiatric and neurological disorders. The method of finding new drugs has been completely transformed by Computer-Aided Drug Design (CADD), which combines medicinal chemistry concepts with computer tools. This review explores the applications of CADD in the development of psychotropic and neurological drugs. Beginning with an overview of psychotropic and neurological disorders, the article delves into the challenges faced in traditional drug discovery methods. It then elucidates the principles and methodologies of CADD, including molecular docking, pharmacophore modeling, and quantitative structure-activity relationship (QSAR) analysis. Subsequently, case studies highlight successful applications of CADD in the identification and optimization of lead compounds targeting various psychotropic and neurological targets. Finally, the review discusses future prospects and challenges in the field, emphasizing the potential of CADD to expedite the discovery of novel therapeutics for these debilitating disorders.

Keywords: ligand-based drug design; docking; QSAR; pharmacophore; Alzheimer's disease; structure-based drug design; schizophrenia; neuropathic pain; neurological; deep learning; molecular dynamics; psychotropic; virtual screening; computer-aided drug design; artificial intelligence

INTRODUCTION

Worldwide, neurological and psychiatric illnesses provide serious obstacles to public health. Conditions such as depression, schizophrenia, Alzheimer's disease, and Parkinson's disease not only have a profound impact on the quality of life of affected individuals but also place a considerable burden on healthcare systems [1]. Traditional drug discovery methods for these disorders have often been slow, costly, and plagued by high rates of failure [2]. However, recent advancements in computational techniques have provided new avenues for accelerating the process of drug discovery and development. Researchers have accelerated the identification of promising drug candidates, optimised their pharmacological properties, and gained new insights into the underlying molecular mechanisms of neurological and psychiatric illnesses by combining computational tools with experimental procedures [3]. By leveraging molecular modeling, virtual screening, and other computational

***Author for Correspondence**
Satish Kumar Yadav
E-mail: slk.pharma@gmail.com

[1]Principal, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P, India
[2]Academic Head, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P, India
[3]Research Scholar, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P., India
[4]Associate Professor, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur, U.P., India
[5]Lecturer, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur U.P., India

Received Date: May 10, 2024
Accepted Date: May 14, 2024
Published Date: July 09, 2024

Citation: Mohd. Wasiullah, Piyush Yadav, Safiya Sajid, Satish Kumar Yadav, Anjali Maurya. An Extensive Analysis of Computer-aided Drug Design for Novel Psychotropic and Neurological Substances. International Journal of Brain Sciences. 2024; 1(2): 15–23p.

techniques, CADD offers a systematic and cost-effective approach to drug discovery that complements and enhances traditional experimental methods [2]. Throughout this review, we will examine the applications of CADD in the discovery of psychotropic and neurological drugs, highlighting key successes and challenges in the field. Furthermore, we will discuss emerging trends and future directions in CADD, as well as the ethical and regulatory considerations that accompany its use in pharmaceutical research and development. By providing a comprehensive overview of the role of CADD in psychotropic and neurological drug discovery, this review aims to underscore the importance of computational approaches in addressing the unmet medical needs of individuals affected by psychiatric and neurological disorders [4]. CADD has the ability to revolutionize drug development and open the door to a new age of individualized medicine for neurological and mental health conditions with further innovation and cooperation [2].

TRADITIONAL DRUG DISCOVERY METHODS

Overview

Traditional drug discovery methods have historically relied on a combination of high-throughput screening (HTS) and rational drug design approaches. Large compound libraries are screened as part of HTS in order to find compounds that may have therapeutic promise against a target of interest [2]. Conversely, rational drug design makes use of the target's structure and function knowledge to create compounds with the desired pharmacological characteristics [1]. Despite their widespread use, traditional drug discovery methods suffer from several limitations. HTS campaigns are often expensive and time-consuming, requiring substantial resources for the synthesis and testing of large numbers of compounds [2]. Additionally, HTS may yield hits with low potency, selectivity, or pharmacokinetic properties, necessitating further optimization. Rational drug design approaches, while conceptually appealing, are hindered by the complexity of biological systems and the limited availability of structural information for many drug targets [3].

Need for Alternative Approaches

The challenges associated with traditional drug discovery methods underscore the need for alternative approaches to accelerate the identification and development of novel therapeutics for psychiatric and neurological disorders. Providing a range of computational tools and methodologies to expedite the drug development process, computer-aided drug design (CADD) has emerged as a possible answer to these problems [4].

FUNDAMENTALS OF COMPUTER-AIDED DRUG DESIGN

Ligand Based Techniques

By leveraging similarities between the compounds under investigation and a known ligand or group of known ligands, a technique known as "ligand-based drug design" (LBDD) predicts the activity of additional small molecules [3]. This operates under the tenet that substances with comparable chemical structures will have comparable binding characteristics [1].

2D Based Methods

In 2D methods, chemical structure is expressed as a collection of descriptors that are subsequently utilized to identify molecules with comparable characteristics. A 2D molecular graph is used to compute a variety of physicochemical characteristics and molecular attributes [1]. Based on Lipinski's rule of five, these characteristics—such as molecular weight and logP—are crucial for determining a molecule's eligibility as a medication. Thus, the physicochemical characteristics also tell us about the likelihood of a ligand crossing the blood-brain barrier (BBB), an important factor in the creation of CNS drugs [5]. A 2D molecular network can also yield molecular attributes such as fragment counts, substructure counts, and topological indices. The physicochemical and molecular characteristics offer the information required to discover new.

Modelling Pharmacophores

A set of chemical characteristics known as a pharmacophore model describes how a ligand interacts with a biological target to clarify a physiological response. Pharmacophore modeling is another

method for determining if a ligand would function as an agonist or antagonist [5]. This strategy is especially helpful in situations where it is difficult to obtain comprehensive knowledge about the target structure. Pharmacophore modelling also provides indirect information regarding binding site characteristics based on the chemical characteristics of known active compounds [6]. Using pharmacophore modeling, antagonists of the α7 nicotinic acetylcholine receptor (nAChR) have been looked after prior to the resolution of the protein's 3D structure. T761-0184, a high potency lead, was discovered, offering a new therapy option for CNS illnesses like.



Figure 1. A fuchsia and green example pharmacophore of two recognised P2X7 antagonists.

A fuchsia and green example pharmacophore of two recognised P2X7 antagonists is shown in Figure 1. Similar molecular characteristics of the ligands have been grouped together so that they align with the pharmacophore. There are five main characteristics of this sample pharmacophore. Orange rings stand in for two aromatic groups, pink spheres for two hydrogen bond acceptors, and light blue spheres for two hydrogen bond donors. The exclusion volumes, which encircle these features in a grey sphere, are representative of the predicted structure of the protein binding pocket. To avoid steric conflicts, question ligands must thus not penetrate these areas. It is anticipated that the combination of these characteristics would primarily influence drug receptor interactions [7].

QSAR

The association between a molecule's topological characteristics and physicochemical characteristics and the biological activity they exhibit on a target serves as the foundation for the idea of the quantitative structure–activity relationship, or QSAR [8]. This connection is used in QSAR investigations to rank and filter libraries of compounds and forecast biological activity [1]. Molecular descriptors like binding affinity (KD) or functional potency (EC50 or IC50) values are linked to biological data through statistical techniques that enable these forecasts. For the purpose of training and testing QSAR models, data can be accessed through chemical databases or, more frequently, through internal sources (such as proprietary data). When creating a medication with several targets, these prediction models are quite helpful [9]. QSAR simulations.

Methods Based on Structure

When the three-dimensional structure of a biological target is known, a subsection of CADD known as "structure-based drug design" (SBDD) is employed. Understanding a ligand binding site's composition enables compound libraries to be screened and molecules to be specifically designed to meet the site as best as possible [10]. The collection of 3D structures of significant pharmacological targets is growing quickly due to recent developments in cryogenic electron microscopy (cryo-EM) technology and crystallisation procedures. Furthermore, with the completion of the Human Genome Project and the introduction of artificial intelligence-based structure prediction algorithms like as

RoseTTAFold and AlphaFold2, protein structures can now be predicted only from sequence [6]. Additionally, the expansion of high-performance computing and the use of graphical.

Molecular Docking and Homology Modelling

An SBDD method called "molecular docking" forecasts a ligand's preferred shape and orientation within a binding site. It can be used to rate the ligands in order to help identify possible hit molecules, as well as search databases of ligands and provide ratings for the estimated binding energy [11]. In molecular docking studies, potential ligand poses are investigated by letting the ligand to be flexible during protein binding. This ensures that each ligand-protein complex's lowest possible energy state will be found when rating and ranking the ligands [11]. Depending on the search strategy used, conformers are either produced a-priori, by methodically investigating every potential degree of freedom with regard to ligand binding, or by arbitrarily changing parameters, including torsional angles [6]. After ligand.

Research on Molecular Dynamics

Docking only examines one frame in time, but proteins and ligands are present in a dynamic, complex biological milieu in contact with water, membranes, and ions [12]. This can be explained by using molecular dynamics (MD), a method that can be used either before or after docking to examine the flexibility, stability, conformation, and ligand sampling of proteins. Protein structures that are inflexible or have localized movements are typically the focus of conventional docking studies; in contrast, MD naturally mimics the dynamic protein system and takes protein structural changes into account. This is due to MD's ability to imitate and account for motion [13]. The validation of docking data was done while looking into LRRK2 antagonists as potential novel Parkinson's disease therapeutics. The MD models offered.

Molecular Modeling

Molecular modeling encompasses a range of computational techniques used to simulate and visualize the three-dimensional structures of molecules. These techniques include molecular mechanics, quantum mechanics, and molecular dynamics simulations [7]. Through the use of mathematical algorithms and physical principles, molecular modeling enables researchers to investigate the energetics and interactions of molecules at the atomic level. Molecules are represented as collections of atoms and bonds [13].

Molecular Docking

A computational technique called molecular docking is used to forecast how tiny compounds will bind to a target protein and with what affinity. Docking algorithms search for energetically favorable configurations of ligands within the binding site of the protein, taking into account factors such as steric complementarity, electrostatic interactions, and hydrogen bonding [9]. Docking studies play a crucial role in virtual screening and lead optimization efforts by guiding the selection and optimization of potential drug candidates [11].

Virtual Screening

In virtual screening, a vast compound library is computationally screened to find compounds that may be active against a target of interest. Virtual screening methods can be divided into structure-based and ligand-based approaches [14]. Structure-based virtual screening relies on the three-dimensional structure of the target protein to predict binding interactions with small molecules, while ligand-based approaches utilize information about known ligands or bioactive compounds to identify structurally similar molecules with desired pharmacological properties [15].

Applications of CADD in Psychotropic Drug Discovery

Target Identification and Validation

CADD plays a crucial role in the identification and validation of drug targets for psychotropic disorders. Computational methods, such as molecular docking and virtual screening, can be used to

explore the interactions between potential drug candidates and target proteins implicated in psychiatric disorders, including neurotransmitter receptors, transporters, and enzymes [16]. By identifying novel drug targets and elucidating their molecular mechanisms, CADD facilitates the discovery of new therapeutic interventions for conditions such as depression, schizophrenia, and anxiety [17].

Lead Identification and Optimization

Once potential drug targets have been identified, CADD can aid in the identification and optimization of lead compounds with desired pharmacological properties [18]. Virtual screening of compound libraries against target structures allows researchers to rapidly identify hits with potential activity against psychiatric disorders [19]. Molecular docking studies enable the prediction of ligand-binding modes and affinity, guiding the selection and optimization of lead compounds through structure-activity relationship (SAR) analysis [18, 19]. By iteratively refining lead structures based on computational predictions and experimental validation, CADD accelerates the drug discovery process and improves the likelihood of success in clinical trials[19].

Polypharmacology and Network Pharmacology

Psychiatric disorders often involve complex interactions between multiple molecular targets and pathways [19]. CADD enables researchers to explore the polypharmacology of drug candidates by predicting their interactions with multiple targets implicated in psychiatric disorders. Network pharmacology approaches combine computer modeling and network analysis tools to clarify the relationships between drugs, targets, and biological processes associated with psychiatric diseases [12]. By considering the holistic effects of drug candidates on interconnected signaling networks, CADD facilitates the identification of synergistic drug combinations and the development of multi-targeted therapies for psychiatric disorders [20].

Predictive Toxicology and Adverse Drug Reactions

In addition to predicting therapeutic efficacy, CADD can also be used to assess the safety profile of drug candidates and predict potential adverse drug reactions (ADRs) [15]. Computational models for predictive toxicology leverage molecular descriptors and structural features to estimate the likelihood of compounds causing toxicity or ADRs [21]. By identifying potential safety concerns early in the drug discovery process, CADD helps prioritize lead compounds with favorable safety profiles and reduces the risk of late-stage failures in clinical development [22].

Case Studies

This section will include case studies highlighting successful applications of CADD in the discovery of psychotropic drugs [23]. Examples may include the development of selective serotonin reuptake inhibitors (SSRIs) for depression, atypical antipsychotics for schizophrenia, and anxiolytics for anxiety disorders. Each case study will illustrate how computational methods have contributed to the identification, optimization, and characterization of drug candidates, ultimately leading to clinical success [17].

APPLICATIONS OF CADD IN NEUROLOGICAL DRUG DISCOVERY

Alzheimer's Disease

Amyloid-beta plaques and neurofibrillary tangles build up in the brain during Alzheimer's disease (AD), which causes cognitive decline and memory loss [16]. CADD has been instrumental in the development of drugs targeting key pathological mechanisms associated with AD, including beta-secretase (BACE) inhibition, gamma-secretase modulation, and tau protein aggregation inhibition [19]. Computational methods have aided in the identification of small molecule inhibitors and modulators of these targets, as well as in the optimization of drug candidates with improved pharmacokinetic properties and blood-brain barrier penetration [11].

Parkinson's Disease

Motor dysfunction and other symptoms are caused by the progressive degradation of dopaminergic neurons in the brain's substantia nigra region, which is the hallmark of Parkinson's disease (PD) [12]. CADD has contributed to the discovery of drugs targeting various aspects of PD pathology, including dopamine receptor agonists, monoamine oxidase inhibitors, and adenosine A2A receptor antagonists [17]. The development of innovative therapeutics for Parkinson's disease (PD) has been made possible by computational methodologies that have eased the creation and optimisation of drug candidates with improved selectivity, effectiveness, and tolerance [14, 16].

Epilepsy

Epilepsy is a neurological disorder characterized by recurrent seizures, which result from abnormal neuronal activity in the brain [15]. CADD has played a significant role in the discovery of antiepileptic drugs (AEDs) targeting ion channels, neurotransmitter receptors, and other molecular targets involved in seizure generation and propagation [22, 16]. By employing virtual screening, molecular docking, and QSAR analysis, researchers have identified novel AEDs with improved efficacy and safety profiles compared to existing treatments [24]. Computational methods have also facilitated the repurposing of existing drugs for epilepsy and the development of combination therapies to improve seizure control [25].

Neurodegenerative Disorders

CADD has been used to find treatments for neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), in addition to Alzheimer's disease (AD) and Parkinson's disease (PD) [15]. Computational methods have aided in the identification of targets and pathways implicated in these disorders, as well as in the design of small molecule modulators and biologics for therapeutic intervention [16]. By leveraging structural and functional insights provided by computational models, researchers can accelerate the development of disease-modifying therapies for neurodegenerative disorders and improve outcomes for affected individuals [18].

CHALLENGES AND FUTURE DIRECTIONS

Accuracy and Predictive Power

One of the primary challenges in computer-aided drug design (CADD) is ensuring the accuracy and predictive power of computational models [8]. While computational techniques have advanced significantly in recent years, there remains a need to improve the reliability of predictions, particularly in complex biological systems [15]. Addressing this challenge requires the development of more accurate force fields, quantum mechanical methods, and machine learning algorithms, as well as the integration of experimental data to validate computational predictions [20].

Incorporating Pharmacokinetic Considerations

In addition to predicting binding affinities and interactions, CADD must also consider pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) [13]. Ensuring the safety and bioavailability of medication candidates in vivo requires optimizing these qualities [6]. Integrating pharmacokinetic considerations into computational models requires the development of accurate ADME prediction algorithms and the incorporation of physiologically relevant parameters into virtual screening and lead optimization workflows [16].

Addressing Drug Resistance and Polypharmacology

The emergence of drug resistance and the complexity of polypharmacology present significant challenges in drug discovery [26]. Computational methods must account for the potential for resistance mutations and the interactions between multiple drug targets and pathways [17].Strategies for addressing drug resistance include the design of multi-targeted therapies, the identification of synergistic drug combinations, and the development of drugs with broad-spectrum activity against

related targets[13]. CADD can play a critical role in elucidating the mechanisms of drug resistance and optimizing therapeutic strategies to overcome resistance mechanisms [25].

Ethical and Regulatory Considerations

It is crucial to think about the moral and legal ramifications of using CADD in pharmaceutical research and development as it develops [14]. Data privacy, informed permission, and the appropriate application of computer models in decision-making are a few examples of ethical concerns [13]. Regulatory agencies play a crucial role in ensuring the safety and efficacy of drugs developed using CADD, and guidelines for the validation and qualification of computational models are needed to support regulatory decision-making [26].

CONCLUSION

In conclusion, ethical and regulatory considerations are integral to the responsible use of computer-aided drug design in pharmaceutical research and development. By upholding principles of data privacy, informed consent, transparency, and accountability, researchers can ensure that CADD contributes to the advancement of science and medicine in an ethical and socially responsible manner. Through collaboration, dialogue, and adherence to ethical guidelines and regulatory standards, CADD has the potential to improve patient outcomes and address unmet medical needs while upholding ethical principles and values.

Summary of Key Findings

The revolutionary significance of computer-aided drug design (CADD) in the discovery and development of novel psychotropic and neurological medications has been examined in this thorough analysis. Beginning with an overview of traditional drug discovery methods and their limitations, we highlighted the importance of CADD as a complementary approach to accelerate the drug discovery process. We discussed the fundamentals of CADD, including molecular modeling, molecular docking, virtual screening, and quantitative structure-activity relationship (QSAR) analysis, and examined their applications in psychotropic and neurological drug discovery.

Applications in Psychotropic and Neurological Drug Discovery

Through case studies and examples, we demonstrated how CADD has facilitated target identification, lead optimization, and polypharmacology in the development of drugs for psychiatric and neurological disorders. From Alzheimer's disease to epilepsy, CADD has contributed to the discovery of innovative therapies targeting diverse molecular mechanisms and pathways implicated in these disorders. By leveraging computational techniques, researchers have overcome traditional challenges and accelerated the translation of basic research into clinical interventions.

REFERENCES

1. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nature genetics. 2019 Mar;51(3):404-13.
2. Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr JM, Goate AM. GWAS on family history of Alzheimer’s disease. Translational psychiatry. 2018 May 18;8(1):99.
3. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, Van Der Lee SJ, Amlie-Wolf A, Bellenguez C. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature genetics. 2019 Mar;51(3):414-30.
4. De Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, Pedersen NL, Stringa N, Zettergren A, Hernández I, Montrreal L. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores. Nature communications. 2021 Jun 7;12(1):3417.
5. Schwartzentruber J, Cooper S, Liu JZ, Barrio-Hernandez I, Bello E, Kumasaka N, Young AM, Franklin RJ, Johnson T, Estrada K, Gaffney DJ. Genome-wide meta-analysis, fine-mapping and

integrative prioritization implicate new Alzheimer's disease risk genes. Nature genetics. 2021 Mar;53(3):392-402.
6. Patel T, Brookes KJ, Turton J, Chaudhury S, Guetta-Baranes T, Guerreiro R, Bras J, Hernandez D, Singleton A, Francis PT, Hardy J. Whole-exome sequencing of the BDR cohort: evidence to support the role of the PILRA gene in Alzheimer's disease. Neuropathology and applied neurobiology. 2018 Aug;44(5):506-21.
7. Raghavan NS, Brickman AM, Andrews H, Manly JJ, Schupf N, Lantigua R, Wolock CJ, Kamalakaran S, Petrovski S, Tosto G, Vardarajan BN. Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease. Annals of clinical and translational neurology. 2018 Jul;5(7):832-42.
8. Chan HS, Li Y, Dahoun T, Vogel H, Yuan S. New binding sites, new opportunities for GPCR drug discovery. Trends in biochemical sciences. 2019 Apr 1;44(4):312-30.
9. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Rongve A, Børte S, Winsvold BS, Drange OK, Martinsen AE, Skogholt AH. Largest GWAS (N= 1,126,563) of Alzheimer's disease implicates microglia and immune cells. MedRxiv. 2020 Nov 23:2020-11.
10. Bellenguez C, Küçükali F, Jansen I, Andrade V, Moreno-Grau S, Amin N, Naj AC, Grenier-Boley B, Campos-Martin R, Holmans PA, Boland A. New insights on the genetic etiology of Alzheimer's and related dementia. MedRxiv. 2020 Oct 4:2020-10.
11. Ray R. Understanding the Structural Importance of the Non-Binding and Binding Parts of Bedaquiline and Its Analogues with ATP Synthase Subunit C Using Molecular Docking, Molecular Dynamics Simulation and 3D-QSAR Techniques. InProceedings of International Conference on Drug Discovery (ICDD) 2020 Feb 19.
12. Du M, Qiu Y, Li Q, Li Y. Efficacy coefficient method assisted quadruple-activities 3D-QSAR pharmacophore model for application in environmentally friendly PAE molecular modification. Environmental Science and Pollution Research. 2020 Jul;27:24103-14.
13. Kotzabasaki MI, Sotiropoulos I, Sarimveis H. QSAR modeling of the toxicity classification of superparamagnetic iron oxide nanoparticles (SPIONs) in stem-cell monitoring applications: an integrated study from data curation to model development. RSC advances. 2020;10(9):5385-91.
14. Zerroug A, Belaidi S, BenBrahim I, Sinha L, Chtita S. Virtual screening in drug-likeness and structure/activity relationship of pyridazine derivatives as Anti-Alzheimer drugs. Journal of King Saud University-Science. 2019 Oct 1;31(4):595-601.
15. Ray R. Understanding the Structural Importance of the Non-Binding and Binding Parts of Bedaquiline and Its Analogues with ATP Synthase Subunit C Using Molecular Docking, Molecular Dynamics Simulation and 3D-QSAR Techniques. InProceedings of International Conference on Drug Discovery (ICDD) 2020 Feb 19.
16. Morales-Navarro S, Prent-Peñaloza L, Rodríguez Núñez YA, Sánchez-Aros L, Forero-Doria O, González W, Campilllo NE, Reyes-Parada M, Martínez A, Ramírez D. Theoretical and experimental approaches aimed at drug design targeting neurodegenerative diseases. Processes. 2019 Dec 10;7(12):940.
17. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology. 2019 Oct;15(10):565-81.
18. Fan F, Toledo Warshaviak D, Hamadeh HK, Dunn RT. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs. PloS one. 2019 Jan 3;14(1):e0204378.
19. Espinoza-Moraga M, Caballero J, Gaube F, Winckler T, Santos LS. 1-Benzyl-1, 2, 3, 4-Tetrahydro-β-Carboline as Channel Blocker of N-Methyl-d-Aspartate Receptors. Chemical Biology & Drug Design. 2012 Apr;79(4):594-9.
20. Schmiedel JM, Lehner B. Determining protein structures using deep mutagenesis. Nature genetics. 2019 Jul;51(7):1177-86.
21. Gbeddy G, Egodawatta P, Goonetilleke A, Ayoko G, Chen L. Application of quantitative structure-activity relationship (QSAR) model in comprehensive human health risk assessment of

PAHs, and alkyl-, nitro-, carbonyl-, and hydroxyl-PAHs laden in urban road dust. Journal of hazardous materials. 2020 Feb 5;383:121154.
22. Morales-Navarro S, Prent-Peñaloza L, Rodríguez Núñez YA, Sánchez-Aros L, Forero-Doria O, González W, Campilllo NE, Reyes-Parada M, Martínez A, Ramírez D. Theoretical and experimental approaches aimed at drug design targeting neurodegenerative diseases. Processes. 2019 Dec 10;7(12):940.
23. Vieira T, Magalhaes R, Sousa S. Tailoring specialized scoring functions for more efficient virtual screening. Frontiers. 2019;2:1-4.
24. Makarasen A, Kuno M, Patnin S, Reukngam N, Khlaychan P, Deeyohe S, Intachote P, Saimanee B, Sengsai S, Boonsri P, Chaivisuthangkura A. Molecular docking studies and synthesis of amino-oxy-diarylquinoline derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Drug Research. 2019 Dec;69(12):671-82.
25. Wang B, Dai P, Ding D, Del Rosario A, Grant RA, Pentelute BL, Laub MT. Affinity-based capture and identification of protein effectors of the growth regulator ppGpp. Nature chemical biology. 2019 Feb;15(2):141-50.
26. Kumar J, Ranjan T, Kumar RR, Ansar M, Rajani K, Kumar M, Kumar V, Kumar A. In silico characterization and homology Modelling of Potato Leaf Roll Virus (PLRV) coat protein. Current Journal of Applied Science and Technology. 2019 Mar 5;33(2):1-8.

